Cargando…
Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database
PURPOSE: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are highly effective and safe against juvenile idiopathic arthritis (JIA), which is classified into systemic JIA (sJIA) and the other JIA categories (non-sJIA) according to differences in clinical symptoms and pathophysiology. The pu...
Autores principales: | Hata, Takeo, Hirata, Atsushi, Ota, Ryosuke, Hosohata, Keiko, Nishihara, Masami, Neo, Masashi, Katsumata, Takahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422327/ https://www.ncbi.nlm.nih.gov/pubmed/36046102 http://dx.doi.org/10.2147/TCRM.S375890 |
Ejemplares similares
-
Non-Rheumatic Chronic Comorbidities in Children with Juvenile Idiopathic Arthritis
por: Haşlak, Fatih, et al.
Publicado: (2023) -
Burden of Asthma in Elderly Japanese Patients: Using Hospital-Based Administrative Claims Data
por: Sato, Keiko, et al.
Publicado: (2020) -
Analysis of nationwide hemophilia care: A cohort study using two Japanese healthcare claims databases
por: Kinai, Ei, et al.
Publicado: (2022) -
Celiac Disease in Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Disorders
por: Poddighe, Dimitri, et al.
Publicado: (2022) -
Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan
por: Toyoda, Katsunori, et al.
Publicado: (2021)